Table 1.
Association between baseline clinicopathological characteristics of the study population and kyn/trp ratio.
| Characteristics | N (%) | Median (range) | Serum kyn/trp ratio (mean ± SD) | P-value |
|---|---|---|---|---|
| AGE | 65 (44–85) | |||
| >65 | 31 (56.4) | 0.056 ± 0.038 | 0.121 | |
| <65 | 24 (43.6) | 0.048 ± 0.029 | ||
| BMI | 22.4 (16.9–37.5) | |||
| Normal | 39 (70.9) | 0.058 ± 0.031 | 0.839 | |
| Overweight/obese | 13 (23.6) | 0.054 ± 0.040 | ||
| Underweight | 3 (5.5) | 0.056 ± 0.025 | ||
| SEX | ||||
| Male | 39 (70.9) | 0.059 ± 0.037 | 0.044* | |
| Female | 16 (29.1) | 0.048 ± 0.020 | ||
| HISTOLOGY | ||||
| Clear cell carcinoma | 15 (27.3) | 0.036 ± 0.024 | 0.054 | |
| Squamous NSCLC | 19 (34.5) | 0.060 ± 0.04 | ||
| Adenocarcinoma | 6 (10.9) | 0.100 ± 0.04 | ||
| Undifferentiated NSCLC | 1 (1.8) | 0.040 | ||
| Squamous HNSCC | 14 (25.5) | 0.055 ± 0.034 | ||
| BASELINE (ECOG) PS | ||||
| PS 0 | 38 (69.1) | 0.053 ± 0.025 | 0.054 | |
| PS 1 | 17 (30.9) | 0.056 ± 0.047 | ||
| BRAIN METASTASIS | ||||
| Yes | 6 (10.9) | 0.064 ± 0.034 | 0.905 | |
| No | 47 (89.1) | 0.055 ± 0.035 | ||
| LUNG METASTASIS | ||||
| Yes | 40 (72.7) | 0.053 ± 0.029 | 0.017* | |
| No | 15 (27.2) | 0.080 ± 0.046 | ||
| PLEURAL EFFUSION | ||||
| Yes | 6 (10.9) | 0.062 ± 0.051 | 0.096 | |
| No | 49 (89.1) | 0.054 ± 0.032 | ||
| LIVER METASTASIS | ||||
| Yes | 9 (16.4) | 0.062 ± 0.050 | 0.076 | |
| No | 46 (83.6) | 0.054 ± 0.030 | ||
| EARLY PROGRESSOR | ||||
| Yes | 29 (52.7) | 0.056 ± 0.042 | 0.047* | |
| No | 26 (47.3) | 0.050 ± 0.021 | ||
kyn, kynurenine; trp, tryptophan; SD, standard deviation; BMI, body mass index; NSCLC, non-small cell lung cancer; HNSCC, head and neck squamous cell carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; *Statistical significance was set at p < 0.05.